scholarly journals Efficacy and safety of a 3-month loteprednol etabonate 0.5% gel taper for routine prophylaxis after photorefractive keratectomy compared to a 3-month prednisolone acetate 1% and fluorometholone 0.1% taper

2017 ◽  
Vol Volume 11 ◽  
pp. 1113-1118 ◽  
Author(s):  
Mark Mifflin ◽  
Brent Betts ◽  
Adam Frederick ◽  
Jason Feuerman ◽  
Carlton Fenzl ◽  
...  
Keyword(s):  
Photorefractive Keratectomy ◽  
Prednisolone Acetate ◽  
Efficacy And Safety ◽  
Loteprednol Etabonate ◽  
Routine Prophylaxis

scholarly journals Comparison of efficacy and safety of postoperative treatment with loteprednol etabonate and bromfenac after phacoemulsification

Klinika Oczna ◽  
2019 ◽  
Vol 2019 (1) ◽  
pp. 18-22
Author(s):  
Magdalena Kucharczyk-Pośpiech ◽  
Piotr Jurowski ◽  
Wiktoria Kubisiak ◽  
Monika Chwiałkowska-Karam ◽  
Michał Wilczyński ◽  
...  
Keyword(s):  
Postoperative Treatment ◽  
Efficacy And Safety ◽  
Loteprednol Etabonate

scholarly journals Ophthalmic medication price variation across the United States: Anti-inflammatory medications

2019 ◽  
Vol 11 ◽  
pp. 251584141986363
Author(s):  
Anthony T. Scott ◽  
Paula E. Pecen ◽  
Alan G. Palestine
Keyword(s):  
United States ◽  
Sodium Phosphate ◽  
The United States ◽  
Small Subset ◽  
Prednisolone Acetate ◽  
Loteprednol Etabonate ◽  
Price Variation ◽  
Drug Prices ◽  
Anti Inflammatory ◽  
Us Cities

Background: Cost-related nonadherence to medication can impact ophthalmic treatment outcomes. We aimed to determine whether medication prices vary between US cities and between different types of pharmacies within one city. Methods: We conducted a phone survey of eight nationwide and five independent pharmacies in five cities across the United States: Boston, Massachusetts; Charlotte, North Carolina; Denver, Colorado; Detroit, Michigan; and Seattle, Washington. A researcher called each pharmacy asking for price without insurance for four common anti-inflammatory ophthalmic medications: prednisolone acetate, prednisolone sodium phosphate, difluprednate (Durezol™), and loteprednol etabonate (Lotemax™). Results: Prednisolone sodium phosphate price could only be obtained by a small subset of pharmacies (45.2%) and was excluded from additional analysis; however, preliminary data demonstrated lower cost of prednisolone sodium phosphate over prednisolone acetate. Three-way analysis of variance revealed no interaction between pharmacy type (chain versus independent), city, and drug ( F = 0.40, p = 0.92). A significant interaction was identified between pharmacy type and drug ( F = 5.0, p = 0.008), but not city and pharmacy type ( F = 0.66, p = 0.62) or city and drug ( F = 0.27, p = 0.97). Average drug prices were lower at independent pharmacies compared with chain pharmacies for difluprednate (US$211.36 versus US$216.85, F = 1.09, p = 0.297) and significantly lower for loteprednol etabonate (US$255.49 versus US$274.86, F = 14.7, p < 0.001). Prednisolone acetate was cheaper at chain pharmacies, but not statistically significantly cheaper (US$48.82 versus US$51.61, F = 0.34, p = 0.559). Conclusions: Medication prices do not differ significantly between US cities. High variation of drug prices within the same city demonstrates how comparison shopping can provide cost savings for patients and may reduce cost-related nonadherence.

Topical loteprednol etabonate 0.5 % for treatment of vernal keratoconjunctivitis: efficacy and safety

2012 ◽  
Vol 56 (4) ◽  
pp. 312-318 ◽  
Author(s):  
Veysi Öner ◽  
Fatih Mehmet Türkcü ◽  
Mehmet Taş ◽  
Mehmet Fuat Alakuş ◽  
Yalçın İşcan
Keyword(s):  
Vernal Keratoconjunctivitis ◽  
Efficacy And Safety ◽  
Loteprednol Etabonate

scholarly journals Longitudinal Efficacy and Safety of N8-GP for Prophylaxis and Bleed Control in US Patients

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 3205-3205
Author(s):  
Allison P. Wheeler ◽  
Miguel A. Escobar ◽  
Susan Kearney ◽  
Janice M. Staber ◽  
Adam R. Wufsus ◽  
...  
Keyword(s):  
Board Of Directors ◽  
Research Funding ◽  
Hemophilia A ◽  
Treatment Success ◽  
Efficacy And Safety ◽  
Advisory Committees ◽  
On Demand ◽  
Routine Prophylaxis ◽  
Previously Treated ◽  
Extension Trial

Abstract Introduction: N8-GP is an extended half-life recombinant factor VIII product indicated for use in patients with hemophilia A. The pathfinder trials evaluated routine prophylaxis and bleed control in previously treated patients aged ≥12 years (pathfinder2) and patients aged &lt;12 years (pathfinder5), including an extension trial (pathfinder8). The objective of the present analysis was to compare the efficacy and safety of N8-GP in US vs global (including US) patients. Methods: In the pathfinder2 trial, patients aged ≥12 years with severe hemophilia A were administered N8-GP 50 IU/kg every 4 days (Q4D) as routine prophylaxis or 20 to 70 IU/kg as on-demand treatment. Patients aged &lt;12 years received prophylaxis with N8-GP 60 IU/kg twice weekly in the pathfinder5 trial, and bleeding episodes were treated with 20 to 75 IU/kg. In the pathfinder8 extension trial, the investigator decided on which treatment arm the patient should be allocated based on previous treatment regimen and taking into account bleeding tendency. Results: See Table for efficacy in prophylaxis (median annualized bleeding rates [ABRs]) and bleed treatment (success rate). Median ABRs tended to decrease from 0.84 (global) and 0.86 (US) in pathfinder2 to 0.00 (global) and 0.00 (US) in pathfinder8 in patients aged ≥12 years on the prophylaxis regimen. In addition, in patients aged &lt;12 years, median ABRs decreased from 0.81 (global) and 0.76 (US) in pathfinder5 to 0.00 (global) and 0.49 (US) in pathfinder8. Treatment success rates for US patients were comparable to those for global patients across trials and 100% were rated "excellent" or "good" for patients aged &lt;12 years in pathfinder8. Overall, there were 59 treatment-related adverse events (AEs) in patients on the prophylactic regimen in pathfinder2, 13 of which occurred in US patients, and 11 treatment-related AEs in patients treated on-demand, 3 of which occurred in US patients. In pathfinder5, there were 16 treatment-related AEs, 7 of which occurred in US patients. In pathfinder8, there were 6 treatment-related AEs in patients aged ≥12 years, 3 of which were in US patients. In addition, there was 1 treatment-related AE in a non-US patient aged &lt;12 years. AEs included rash, redness, and injection site reactions. Across trials, 1 previously treated patient (an 18-year-old, from a US site) with an intron 22 inversion developed a low-titer inhibitor at 93 exposure days to N8-GP and was withdrawn when the titer progressed to &gt;5 Bethesda units. The patient returned to their previous FVIII product, and their inhibitor status was negative at follow-up. Conclusions: Efficacy of N8-GP was sustained during the main and extension pathfinder trials in both global and US patients. In addition, a favorable safety profile was maintained throughout the course of the program. Figure 1 Figure 1. Disclosures Wheeler: Novo Nordisk A/S: Consultancy; Bayer: Consultancy; BioMarin: Consultancy; HEMA Biologics: Consultancy; Spark: Consultancy; Takeda: Consultancy; UniQure: Consultancy. Kearney: Grifols: Research Funding; Daiichi Sankyo: Research Funding; CVS Pharmacy: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novo Nordisk Inc: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Bioverativ/Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. Staber: Bayer, CSL Behring, Sanofi, Takeda: Membership on an entity's Board of Directors or advisory committees. Wufsus: Novo Nordisk Inc: Current Employment. Ostrow: Novo Nordisk Inc: Current Employment. Lentz: Novo Nordisk Inc: Consultancy, Honoraria, Research Funding.

A Randomized Controlled Trial Comparing Dexamethasone with Loteprednol Etabonate on Postoperative Photorefractive Keratectomy

2015 ◽  
Vol 31 (3) ◽  
pp. 165-168 ◽  
Author(s):  
Onsiri Thanathanee ◽  
Phornrak Sriphon ◽  
Orapin Anutarapongpan ◽  
Raweewan Athikulwongse ◽  
Prakairat Thongphiew ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Photorefractive Keratectomy ◽  
Loteprednol Etabonate ◽  
Randomized Controlled

The Efficacy and Safety of Diclofenac 0.1% Versus Prednisolone Acetate 1% Following Trabeculectomy With Adjunctive Mitomycin-C

1998 ◽  
Vol 29 (7) ◽  
pp. 562-569
Author(s):  
Alexander R Kent ◽  
Harvey B Dubiner ◽  
Roy Whitaker ◽  
Thomas K Mundorf ◽  
Jeanette A Stewart ◽  
...  
Keyword(s):  
Mitomycin C ◽  
Prednisolone Acetate ◽  
Efficacy And Safety

Efficacy and safety of topical diclofenac in reducing ocular pain after excimer photorefractive keratectomy

1996 ◽  
Vol 22 (5) ◽  
pp. 536-541 ◽  
Author(s):  
Miles K. Tutton ◽  
Paul M.H. Cherry ◽  
Palaniswamy Sunder Raj ◽  
Mario G. Fsadni
Keyword(s):  
Photorefractive Keratectomy ◽  
Efficacy And Safety ◽  
Ocular Pain ◽  
Topical Diclofenac
Sign in / Sign up

Export Citation Format

Share Document